Kiora Pharmaceuticals (KPRX) Announces Chairman Retirement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
September 21, 2023 7:02 AM EDTEncinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring after serving 17 years on the board.
"We look forward to Dr. Tyle's leadership as Chairman, where he'll continue to bring valuable industry experience in guiding our development of new treatments for eye disease," said Brian M. Strem, PhD, President and CEO of Kiora. "We want to thank Paul... More
